tdenv-piv
Vaccineexperimental
Clinical trial activity
6 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
6
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2012 (NCT01666652)
Timeline
2010s
- Jan 1, 2012
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Dengue virusImmunity, active
Dengue virus immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- tdenv-piv
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03141138 | Phase 1 | Jul 1, 2017 | United States Army |
| NCT03110952 | Phase 1 | Jan 1, 2016 | GlaxoSmithKline, State University of New York, Syracuse, United States Army |
| NCT02421367 | Phase 1/Phase 2 (Phase 2) | Aug 1, 2015 | GlaxoSmithKline, United States Army |
| NCT02239614 | Phase 1 | Nov 1, 2014 | United States Army |
| NCT01702857 | Phase 1 | Nov 1, 2012 | GlaxoSmithKline, United States Army, University of Puerto Rico |
| NCT01666652 | Phase 1 | Sep 1, 2012 | GlaxoSmithKline, United States Army |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| United States Army | Government | 6 | 6 | 2 | 2012 |
| GlaxoSmithKline | For profit | 4 | 0 | 2 | 2012 |
| State University of New York, Syracuse | Academic/Hospital | 1 | 0 | 1 | 2016 |
| University of Puerto Rico | Academic/Hospital | 1 | 0 | 1 | 2012 |
4 organizations
Page 1 / 1